Moors & Cabot’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.76M | Buy |
28,039
+1,572
| +6% | +$126K | 0.08% | 235 |
|
|
2025
Q4 | $2.52M | Buy |
26,467
+780
| +3% | +$76.5K | 0.11% | 178 |
|
|
2025
Q3 | $2.51M | Sell |
25,687
-569
| -2% | -$58.9K | 0.11% | 179 |
|
|
2025
Q2 | $2.82M | Sell |
26,256
-844
| -3% | -$85.4K | 0.13% | 154 |
|
|
2025
Q1 | $2.73M | Buy |
27,100
+1,178
| +5% | +$119K | 0.14% | 146 |
|
|
2024
Q4 | $2.32M | Sell |
25,922
-323
| -1% | -$28.4K | 0.11% | 164 |
|
|
2024
Q3 | $2.2M | Sell |
26,245
-298
| -1% | -$23.5K | 0.11% | 172 |
|
|
2024
Q2 | $2.04M | Sell |
26,543
-175
| -0.7% | -$12.8K | 0.11% | 169 |
|
|
2024
Q1 | $1.83M | Sell |
26,718
-3,892
| -13% | -$250K | 0.1% | 194 |
|
|
2023
Q4 | $1.77M | Buy |
30,610
+1,909
| +7% | +$102K | 0.11% | 174 |
|
|
2023
Q3 | $1.52M | Sell |
28,701
-243
| -0.8% | -$12.7K | 0.1% | 193 |
|
|
2023
Q2 | $1.57M | Sell |
28,944
-1,575
| -5% | -$82.3K | 0.1% | 193 |
|
|
2023
Q1 | $1.53M | Sell |
30,519
-1,621
| -5% | -$76.4K | 0.11% | 195 |
|
|
2022
Q4 | $1.49M | Sell |
32,140
-768
| -2% | -$33.3K | 0.1% | 201 |
|
|
2022
Q3 | $1.27M | Sell |
32,908
-2,570
| -7% | -$103K | 0.1% | 212 |
|
|
2022
Q2 | $1.32M | Buy |
35,478
+2,990
| +9% | +$122K | 0.1% | 215 |
|
|
2022
Q1 | $1.44M | Sell |
32,488
-3,193
| -9% | -$138K | 0.09% | 219 |
|
|
2021
Q4 | $1.52M | Buy |
35,681
+1,300
| +4% | +$54.6K | 0.09% | 217 |
|
|
2021
Q3 | $1.5M | Buy |
34,381
+768
| +2% | +$34K | 0.09% | 206 |
|
|
2021
Q2 | $1.44M | Buy |
33,613
+250
| +0.7% | +$10.5K | 0.1% | 201 |
|
|
2021
Q1 | $1.29M | Buy |
33,363
+1,700
| +5% | +$64.3K | 0.1% | 199 |
|
|
2020
Q4 | $1.14M | Buy |
31,663
+1,618
| +5% | +$58.3K | 0.1% | 205 |
|
|
2020
Q3 | $1.15M | Sell |
30,045
-2,987
| -9% | -$115K | 0.11% | 183 |
|
|
2020
Q2 | $1.17M | Buy |
33,032
+12,477
| +61% | +$449K | 0.12% | 171 |
|
|
2020
Q1 | $674K | Sell |
20,555
-10,750
| -34% | -$420K | 0.1% | 200 |
|
|
2019
Q4 | $1.42M | Buy |
31,305
+75
| +0.2% | +$3.14K | 0.14% | 155 |
|
|
2019
Q3 | $1.26M | Sell |
31,230
-282
| -0.9% | -$11.9K | 0.14% | 156 |
|
|
2019
Q2 | $1.36M | Sell |
31,512
-2,757
| -8% | -$106K | 0.17% | 139 |
|
|
2019
Q1 | $1.32M | Sell |
34,269
-7,455
| -18% | -$285K | 0.18% | 133 |
|
|
2018
Q4 | $1.48M | Buy |
41,724
+1,275
| +3% | +$46.2K | 0.23% | 112 |
|
|
2018
Q3 | $1.56M | Sell |
40,449
-3,021
| -7% | -$106K | 0.19% | 133 |
|
|
2018
Q2 | $1.43M | Sell |
43,470
-6,198
| -12% | -$187K | 0.19% | 133 |
|
|
2018
Q1 | $1.36M | Sell |
49,668
-350
| -0.7% | -$9.51K | 0.18% | 142 |
|
|
2017
Q4 | $1.24M | Buy |
50,018
+43
| +0.1% | +$1.19K | 0.16% | 144 |
|
|
2017
Q3 | $1.47M | Buy |
49,975
+1,800
| +4% | +$49.7K | 0.21% | 127 |
|
|
2017
Q2 | $1.35M | Sell |
48,175
-1,350
| -3% | -$35.8K | 0.22% | 124 |
|
|
2017
Q1 | $1.22M | Buy |
49,525
+200
| +0.4% | +$4.86K | 0.21% | 131 |
|
|
2016
Q4 | $1.06M | Buy |
49,325
+2,802
| +6% | +$61.1K | 0.17% | 140 |
|
|
2016
Q3 | $1.11M | Buy |
46,523
+4,398
| +10% | +$105K | 0.19% | 137 |
|
|
2016
Q2 | $990K | Buy |
42,125
+1,250
| +3% | +$27K | 0.17% | 144 |
|
|
2016
Q1 | $775K | Sell |
40,875
-1,100
| -3% | -$19.3K | 0.14% | 187 |
|
|
2015
Q4 | $773K | Buy |
41,975
+1,400
| +3% | +$25.1K | 0.14% | 180 |
|
|
2015
Q3 | $662K | Buy |
40,575
+1,900
| +5% | +$32.5K | 0.12% | 207 |
|
|
2015
Q2 | $686K | Buy |
38,675
+13,425
| +53% | +$240K | 0.11% | 226 |
|
|
2015
Q1 | $448K | Sell |
25,250
-5,000
| -17% | -$79K | 0.07% | 288 |
|
|
2014
Q4 | $402K | Buy |
30,250
+6,900
| +30% | +$88.2K | 0.07% | 309 |
|
|
2014
Q3 | $279K | Buy |
23,350
+500
| +2% | +$6.3K | 0.05% | 397 |
|
|
2014
Q2 | $293K | Buy |
22,850
+4,975
| +28% | +$64.7K | 0.05% | 386 |
|
|
2014
Q1 | $242K | Buy |
+17,875
| New | +$235K | 0.06% | 309 |
|
Other funds holding BSX
VCM
VPM
Moors & Cabot's BSX Position: Q1 2026 in Review
Moors & Cabot increased its Boston Scientific (BSX) stake by 5.9% in Q1 2026, buying an estimated $126K and bringing the position to 28,039 shares worth $1.76M. The position accounts for 0.08% of the portfolio, ranked #235.
Moors & Cabot first reported a position in BSX in Q1 2014 and has held it in 49 quarters since. The position peaked at $2.82M in Q2 2025. 1,671 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Moors & Cabot held 28,039 shares of Boston Scientific worth $1.76M as of Q1 2026.
- Moors & Cabot bought 1,572 Boston Scientific shares in Q1 2026, an estimated $126K.
- Boston Scientific made up 0.08% of Moors & Cabot's portfolio in Q1 2026, its #235 holding.
- Moors & Cabot first reported a position in Boston Scientific in Q1 2014 and has held it in 49 quarters since.
- Moors & Cabot's Boston Scientific position peaked at $2.82M in Q2 2025.
- 1,671 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.